Merge eSign Trial with airSlate SignNow

Integrate esigning trial

Clinical trials are research studies that evaluate new ways to improve treatments and quality of life for people with diseases like pancreatic cancer. Clinical trials are an option for all patients to consider and play an important role in improving healthcare. Results from clinical trials help develop new drugs, new diagnostic tools, and new clinical procedures. Clinical trials can also spur new questions for research, which lead to new discoveries over time and help us to better understand diseases like pancreatic cancer. All the drugs and tools we have today were made possible because patients volunteered for clinical trials. Every clinical trial has what are called “eligibility criteria”. For example, a patient may need to have a certain medical condition, or gender, or other specifics to meet the criteria of participating in the clinical trial. Otherwise they are not eligible to join that clinical trial and could seek another trial that better fits their situation. Patients who want to volunteer need to understand the potential benefits and risks of participation in a clinical trial. Patients may personally benefit from receiving new therapies or procedures. They receive close supervision from clinical staff. Sometimes the cost of the new drugs or testing is free or waived. Participants may also be part of a research breakthrough that helps thousands of future patients. Patients face the risk that they may not benefit from the new treatment. Additionally, participating in a clinical trial requires commitment. Trials can be lengthy or demanding, and may require extra treatments, extra time in the clinic, or tests or costs that are not part of standard care. It is possible, if the study is randomized, that they may be part of the control group that does not receive the new drug being studied. “Informed consent” is a process that helps patients make an informed decision about whether to join a clinical trial. An “informed consent document” will be provided that explains the purpose, procedures, and potential benefits and risks of the trial. There will also be thorough discussions between the doctor and patient so that all questions can be clearly answered. In late-stage clinical trials, participants are generally split into 2 groups at the beginning of the study. One group receives the standard treatment plus the new treatment. This group is called the “Treatment Group”. The other group receives the standard treatment only, and does not receive the new treatment. This group is known as the “Control Group”. A computer is used to randomly assign the patient to either the Treatment Group or the Control Group. Randomization helps to prevent bias because neither the patient nor the doctor can choose which treatment group a patient is assigned to. Some clinical trials may want to study the effectiveness of adding a new treatment to a standard treatment to see what works better. In these studies, half the patients will receive the standard treatment plus the new treatment, and the other half will receive the standard treatment plus a “placebo”. A “placebo”...